If the MOA validates numerous drug synergies (as I suspect it will); it would be remiss of RAC not to pursue these.
JDS' only misstep is that a cheaper buying opportunity would present itself, IMO.
"RAC should focus on one thing!"
What if the doxo synergy were to fail? We'd have forfeited 12 months of patent life, if not longer.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.34 |
Change
-0.015(1.11%) |
Mkt cap ! $231.9M | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.36 | $1.31 | $132.3K | 98.59K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | $1.32 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.34 | 10069 | 2 |
View Market Depth
| Last trade - 15.54pm 20/06/2025 (20 minute delay) ? |
| RAC (ASX) Chart |